Wadi Rouel
Internal Medicine · San Diego, CANPI 1740254713
Payments from drug & device makers
Across 171 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$949
- Lilly USA, LLC$638
- AbbVie$321
- AstraZeneca$279
- Bayer$209
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$205
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,645100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 42 | $949 |
| Lilly USA, LLC | 30 | $638 |
| AbbVie(2 entities) | 15 | $321 |
| AstraZeneca | 14 | $279 |
| Bayer | 10 | $209 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $205 |
| Boehringer Ingelheim | 9 | $198 |
| Ironwood Pharmaceuticals, Inc | 5 | $103 |
| Xeris Pharmaceuticals, Inc. | 4 | $90 |
| Shield Therapeutics Inc | 1 | $62 |
| Amarin Pharma, Inc. | 3 | $61 |
| Dexcom, Inc. | 3 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $56 |
| Exact Sciences | 2 | $49 |
| Pfizer | 2 | $44 |
| Redhill Biopharma Inc. | 1 | $43 |
| Novartis | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Abbott | 2 | $36 |
| Merck | 2 | $33 |
| Amgen | 1 | $29 |
| Boston Scientific | 1 | $29 |
| Mannkind Corporation | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Dermira, Inc. | 1 | $13 |
How this compares
$3,645 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 468 | $325,164 |
| OzempicSemaglutide | 257 | $239,551 |
| TradjentaLinagliptin | 221 | $133,350 |
| TrulicityDulaglutide | 133 | $126,570 |
| EliquisApixaban | 103 | $62,276 |
| LinzessLinaclotide | 114 | $58,579 |
| EntrestoSacubitril/Valsartan | 50 | $34,614 |
| JanuviaSitagliptin Phosphate | 46 | $31,249 |
| XareltoRivaroxaban | 45 | $26,311 |
| FarxigaDapagliflozin Propanediol | 37 | $23,772 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 51 | $17,633 |
| BrilintaTicagrelor | 29 | $14,306 |
| GlyxambiEmpagliflozin/Linagliptin | 21 | $10,524 |
| MultaqDronedarone Hcl | 13 | $9,533 |
| Repatha SureclickEvolocumab | 16 | $8,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $198 | $469,038710 claims |
| Lilly USA, LLCTrulicity | $638 | $126,570133 claims |
| PfizerEliquis | $44 | $62,276103 claims |
| AbbVieLinzess | $321 | $58,579114 claims |
| AstraZenecaFarxiga, Brilinta | $279 | $38,07766 claims |
| NovartisEntresto | $40 | $34,61450 claims |
| MerckJanuvia, Dulera | $33 | $34,48857 claims |
| Johnson & JohnsonXarelto | $17 | $26,31145 claims |
| GSKBreo Ellipta, Anoro Ellipta | $949 | $13,67534 claims |
| Sanofi-aventis U.S. LLCMultaq, Lantus | $56 | $10,78224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Diego
- Donald BrandonSan Diego$34M
- Elaine WatkinsSan Diego$11.3M
- James ChenSan Diego$2.9M
- Rita StarrittSan Diego$2.6M
- Hatim HusainSan Diego$2.6M
- Gary FiresteinSan Diego$2.6M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.